This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
CJC-1295 + GHRP-2 (10 mg Blend)
This information is for research and educational use only.
Quick Reference
What is CJC-1295 + GHRP-2?
Research overview based on the cited scientific literature.
• Goal: Support enhanced GH pulsatility and sustained IGF-1 elevation over a defined research period[1].
• Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality[9][10].
• Lyophilized: Refrigerate at 2–8 °C (35.6–46.4 °F); freeze at −20 °C (−4 °F) for long-term storage exceeding several months.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks for optimal potency.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
• If longer storage of reconstituted solution is needed, aliquot into sterile containers and freeze once; avoid repeated freeze–thaw.
How is CJC-1295 + GHRP-2 studied?
CJC-1295 is a tetrasubstituted GHRH(1–29) analog engineered for extended half-life (~6–8 days) via protection from enzymatic degradation and reversible albumin binding[1]. A single dose can sustain elevated GH for approximately 6 days and IGF-1 elevation for 9–11 days. GHRP-2 is a synthetic hexapeptide ghrelin-mimetic that binds the GH secretagogue receptor (GHS-R1a), triggering acute GH pulses that peak within ~25 minutes[3]. Human research shows that GHRH and growth hormone-releasing peptide pathways can stimulate GH release synergistically[6]. This supports the pathway rationale, while the exact compounds and route in the cited study differ from this blend.
What does the research report about CJC-1295 + GHRP-2?
Observations from preclinical and clinical literature.
• Sustained elevation of GH and IGF-1 levels over extended periods with once-daily or even less frequent dosing[1].
• Long-term pediatric studies (8 months) reported no significant adverse effects or toxicities from GHRP-2 therapy[2].
• GHRP-2 may transiently increase appetite due to ghrelin-like activity[4].
• Mild, transient elevations in ACTH, cortisol, and prolactin may occur shortly after injection but remain within physiological ranges[5].
• CJC-1295 at higher doses may cause transient vasodilatory effects such as facial flushing or brief lightheadedness[1].
• Occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on CJC-1295 + GHRP-2?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
